Current Understanding of Inherited Modifiers of FVIII Pharmacokinetic Variation

References

• White G, Rosendaal F, Aledort LM, et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85(3):560. doi:10.1055/s-0037-1615621
   PubMed Web of Science ®Google Scholar
• Gualtierotti R, Solimeno LP, Peyvandi F. Hemophilic arthropathy: current knowledge and future perspectives. J Thromb Haemost. 2021;19(9):2112–2121. doi:10.1111/jth.15444
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Tuddenham EGD. The hemophilias — from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773–1779. doi:10.1056/NEJM200106073442307
   PubMed Web of Science ®Google Scholar
• Cygan PH, Kouides PA. Regulation and importance of factor VIII levels in hemophilia A carriers. Curr Opin Hematol. 2021;28(5):315–322. doi:10.1097/MOH.0000000000000667
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535–579. doi:10.1056/NEJMoa067659
   PubMed Web of Science ®Google Scholar
• Klamroth R, Windyga J, Radulescu V, et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the Phase 3 PROPEL study. Blood. 2021;137(13):1818–1827. doi:10.1182/blood.2020005673
   PubMed Web of Science ®Google Scholar
• den Uijl IEM, Fischer K, van der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia. 2011;17(1):41–44. doi:10.1111/j.1365-2516.2010.02383.x
   PubMed Web of Science ®Google Scholar
• Ogiwara K, Swystun LL, Paine AS, et al. Factor VIII pharmacokinetics associates with genetic modifiers of VWF and FVIII clearance in an adult hemophilia A population. J Thromb Haemost. 2021;19(3):654–663. doi:10.1111/jth.15183
   PubMed Web of Science ®Google Scholar
• Swystun LL, Ogiwara K, Rawley O, et al. Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients. Blood. 2019;134(11):880–891. doi:10.1182/blood.2019000190
   PubMed Web of Science ®Google Scholar
• Björkman S, Folkesson A, Berntorp E. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting. Haemophilia. 2007;13(1):2–8. doi:10.1111/j.1365-2516.2006.01401.x
   PubMed Web of Science ®Google Scholar
• Collins PW, Björkman S, Fischer K, et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost. 2010;8(2):269–275. doi:10.1111/j.1538-7836.2009.03703.x
   PubMed Web of Science ®Google Scholar
• Fischer K, Pendu R, van Schooten CJ, et al. Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients. PLoS One. 2009;4(8):e6745–e6751. doi:10.1371/journal.pone.0006745
   PubMed Web of Science ®Google Scholar
• Hazendonk HCAM, van Moort I, Mathôt RAA, et al. Setting the stage for individualized therapy in hemophilia: what role can pharmacokinetics play? Blood Rev. 2018;32(4):265–271. doi:10.1016/j.blre.2018.01.001
   PubMed Web of Science ®Google Scholar
• Björkman S, Blanchette VS, Fischer K, et al. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost. 2010;8(4):730–736. doi:10.1111/j.1538-7836.2010.03757.x
   PubMed Web of Science ®Google Scholar
• Fijnvandraat K, Peters M, Ten CJW. Inter‐individual variation in half‐life of infused recombinant factor VIII is related to pre‐infusion von Willebrand factor antigen levels. Br J Haematol. 1995;91(2):474–476. doi:10.1111/j.1365-2141.1995.tb05325.x
   PubMed Web of Science ®Google Scholar
• Shah A, Delesen H, Garger S, Lalezari S. Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia. 2015;21(6):766–771. doi:10.1111/hae.12691
   PubMed Web of Science ®Google Scholar
• Chen ZP, Li PJ, Li G, et al. Pharmacokinetic studies of factor VIII in Chinese boys with severe Hemophilia A: a single-center study. Chin Med J. 2018;131(15):1780–1785. doi:10.4103/0366-6999.233604
   PubMed Web of Science ®Google Scholar
• de Lange M, Snieder H, Ariëns RAS, Spector TD, Grant PJ. The genetics of haemostasis: a twin study. Lancet. 2001;357(9250):101–105. doi:10.1016/S0140-6736(00)03541-8
   PubMed Web of Science ®Google Scholar
• Orstavik KH, Magnus P, Reisner IH, Berg K, Graham JB, Nance W. Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet. 1985;37:89–101.
   PubMed Web of Science ®Google Scholar
• Henrard S, Speybroeck N, Hermans C. Body weight and fat mass index as strong predictors of factor VIII in vivo recovery in adults with hemophilia A. J Thromb Haemost. 2011;9(9):1784–1790. doi:10.1111/j.1538-7836.2011.04431.x
   PubMed Web of Science ®Google Scholar
• Björkman S, Oh MS, Spotts G, et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood. 2012;119(2):612–618. doi:10.1182/blood-2011-07-360594
   PubMed Web of Science ®Google Scholar
• Versloot O, Iserman E, Chelle P, et al. Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: data from the WAPPS database. J Thromb Haemost. 2021;19(8):1896–1906. doi:10.1111/jth.15395
   PubMed Web of Science ®Google Scholar
• Cormier M, Batty P, Tarrant J, Lillicrap D. Advances in knowledge of inhibitor formation in severe haemophilia A. Br J Haematol. 2020;189(1):39–53. doi:10.1111/bjh.16377
   PubMed Web of Science ®Google Scholar
• Hofbauer CJ, Kepa S, Schemper M, et al. FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors. Blood. 2016;128(2):293–296. doi:10.1182/blood-2015-10-675512
   PubMed Web of Science ®Google Scholar
• Pipe SW, Montgomery RR, Pratt KP, Lenting PJ, Lillicrap D. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. Blood. 2016;128(16):2007–2016. doi:10.1182/blood-2016-04-713289
   PubMed Web of Science ®Google Scholar
• Song J, Chen F, Campos M, et al. Quantitative influence of ABO blood groups on factor VIII and its ratio to von Willebrand factor, novel observations from an ARIC study of 11,673 subjects. PLoS One. 2015;10(8):1–11.
   Web of Science ®Google Scholar
• Kepa S, Horvath B, Reitter-Pfoertner S, et al. Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A. Haemophilia. 2015;21(3):343–350. doi:10.1111/hae.12592
   PubMed Web of Science ®Google Scholar
• Vlot AJ, Mauser-Bunschoten EP, Zarkova AG, et al. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A. Thromb Haem. 2000;83(1):65–69. doi:10.1055/s-0037-1613759
   PubMed Web of Science ®Google Scholar
• van Dijk K, van der Bom J, Lenting P, et al. Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica. 2005;90(4):494–498.
   PubMed Web of Science ®Google Scholar
• Garcia-Martínez I, Borràs N, Martorell M, et al. Common genetic variants in ABO and CLEC4M modulate the pharmacokinetics of recombinant FVIII in severe hemophilia A patients. Thromb Haemost. 2020;120(10):1395–1406. doi:10.1055/s-0040-1714214
   PubMed Web of Science ®Google Scholar
• Swystun LL, Lillicrap D. Genetic regulation of plasma von Willebrand factor levels in health and disease. J Thromb Haemost. 2018;16(12):2375–2390. doi:10.1111/jth.14304
   PubMed Web of Science ®Google Scholar
• Deitcher S, Tuller J, Johnson J. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients. Haemophilia. 1999;5(2):88–95.
   PubMed Web of Science ®Google Scholar
• Desch KC, Ozel AB, Siemieniak D, et al. Linkage analysis identifies a locus for plasma von Willebrand factor undetected by genome-wide association. Proc Natl Acad Sci U S A. 2013;110(2):588–593. doi:10.1073/pnas.1219885110
   PubMed Web of Science ®Google Scholar
• Bladbjerg EM, de Maat MPM, Christensen K, Bathum L, Jespersen J, Hjelmborg J. Genetic influence on thrombotic risk markers in the elderly - A Danish twin study. J Thromb Haemost. 2006;4(3):599–607. doi:10.1111/j.1538-7836.2005.01778.x
   PubMed Web of Science ®Google Scholar
• Souto JC, Almasy L, Soria JM, et al. Genome-wide linkage analysis of von Willebrand factor plasma levels: results from the GAIT project. Thromb Haem. 2003;89(3):468–474. doi:10.1055/s-0037-1613375
   PubMed Web of Science ®Google Scholar
• Wang QY, Song J, Gibbs RA, Boerwinkle E, Dong JF, Yu FL. Characterizing polymorphisms and allelic diversity of von Willebrand factor gene in the 1000 Genomes. J Thromb Haemost. 2013;11(2):261–269. doi:10.1111/jth.12093
   PubMed Web of Science ®Google Scholar
• Huffman JE, de Vries PS, Morrison AC, et al. Rare and low-frequency variants and their association with plasma levels of fibrinogen, FVII, FVIII, and VWF. Blood. 2015;31(18):e19–e29. doi:10.1182/blood-2015-02-624551
   Google Scholar
• Smith NL, Chen MH, Dehghan A, et al. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: the CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation. 2010;121(12):1382–1392. doi:10.1161/CIRCULATIONAHA.109.869156
   PubMed Web of Science ®Google Scholar
• Sabater-Lleal M, Huffman JE, de Vries PS, et al. Genome-wide association transethnic meta-analyses identifies novel associations regulating coagulation factor VIII and Von Willebrand factor plasma levels. Circulation. 2019;139(5):620–635. doi:10.1161/CIRCULATIONAHA.118.034532
   PubMed Web of Science ®Google Scholar
• Mufti AH, Ogiwara K, Swystun LL, et al. The common VWF single nucleotide variants c.2365A.G and c.2385T.C modify VWF biosynthesis and clearance. Blood Adv. 2018;2(13):1585–1594. doi:10.1182/bloodadvances.2017011643
   PubMed Web of Science ®Google Scholar
• Lenting P, van Schooten C, Denis C. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost. 2007;5(7):1353–1360. doi:10.1111/j.1538-7836.2007.02572.x
   PubMed Web of Science ®Google Scholar
• Mazurier C, Gaucher C, Jorieux S, Goudemand M. Biological effect of desmopressin in eight patients with type 2N (‘Normandy’) von Willebrand disease. Br J Haematol. 1994;88(4):849–854. doi:10.1111/j.1365-2141.1994.tb05127.x
   PubMed Web of Science ®Google Scholar
• Tuddenham EGD, Lane RS, Rotblat F, et al. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand’s disease. Br J Haematol. 1982;52(2):259–267. doi:10.1111/j.1365-2141.1982.tb03888.x
   PubMed Web of Science ®Google Scholar
• Lenting P, Christophe O, Denis C. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood. 2015;125(13):2019–2028. doi:10.1182/blood-2014-06-528406
   PubMed Web of Science ®Google Scholar
• Ward SE, O’Sullivan JM, O’Donnell JS. The relationship between ABO blood group, von Willebrand factor, and primary hemostasis. Blood. 2020;136(25):2864–2874. doi:10.1182/blood.2020005843
   PubMed Web of Science ®Google Scholar
• Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ, Montgomery RA. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987;69(6):1691–1695. doi:10.1182/blood.V69.6.1691.1691
   PubMed Web of Science ®Google Scholar
• Gallinaro L, Cattini MG, Sztukowska M, et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood. 2008;111(7):3540–3545. doi:10.1182/blood-2007-11-122945
   PubMed Web of Science ®Google Scholar
• O’Donnell J, Laffan MA. The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. Transfus Med. 2001;11(4):343–351. doi:10.1046/j.1365-3148.2001.00315.x
   PubMed Web of Science ®Google Scholar
• Albánez S, Ogiwara K, Michels A, et al. Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms. J Thromb Haemost. 2016;14(5):953–963. doi:10.1111/jth.13294
   PubMed Web of Science ®Google Scholar
• O’Donnell J, Boulton FE, Manning RA, Laffan MA. Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol. 2002;22(2):335–341. doi:10.1161/hq0202.103997
   PubMed Web of Science ®Google Scholar
• Swystun LL, Notley C, Georgescu I, et al. The endothelial lectin clearance receptor CLEC4M binds and internalizes factor VIII in a VWF-dependent and independent manner. J Thromb Haemost. 2019;17(4):681–694. doi:10.1111/jth.14404
   PubMed Web of Science ®Google Scholar
• Noe DA. A Mathematical Model of Coagulation FVIII Kinetics. Haemostasis. 1996;26(6):289–303. doi:10.1159/000217222
   PubMedGoogle Scholar
• van Schooten CJ, Shahbazi S, Groot E, et al. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood. 2008;112(5):1704–1712. doi:10.1182/blood-2008-01-133181
   PubMed Web of Science ®Google Scholar
• Navarrete A, Dasgupta S, Delignat S, et al. Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia A. J Thromb Haemost. 2009;7(11):1816–1823. doi:10.1111/j.1538-7836.2009.03571.x
   PubMed Web of Science ®Google Scholar
• Wohner N, Muczynski V, Mohamadi A, et al. Macrophage scavenger receptor SR-A1 contributes to the clearance of von Willebrand factor. Haematologica. 2018;103(4):728–737. doi:10.3324/haematol.2017.175216
   PubMed Web of Science ®Google Scholar
• Rastegarlari G, Pegon JN, Casari C, et al. Macrophage LRP1 contributes to the clearance of von Willebrand factor. Blood. 2012;119(9):2126–2134. doi:10.1182/blood-2011-08-373605
   PubMed Web of Science ®Google Scholar
• Ward SE, O’Sullivan JM, Drakeford C, et al. A novel role for the macrophage galactose-type lectin receptor in mediating von Willebrand factor clearance. Blood. 2018;131(8):911–916. doi:10.1182/blood-2017-06-787853
   PubMed Web of Science ®Google Scholar
• Grewal PK, Uchiyama S, Ditto D, et al. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med. 2008;14(6):648–655. doi:10.1038/nm1760
   PubMed Web of Science ®Google Scholar
• Pegon JN, Kurdi M, Casari C, et al. Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5. Haematologica. 2012;97(12):1855–1863. doi:10.3324/haematol.2012.063297
   PubMed Web of Science ®Google Scholar
• Bovenschen N, Mertens K, Hu L, Havekes LM, van Vlijmen BJM. LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo. Blood. 2005;106(3):906–912. doi:10.1182/blood-2004-11-4230
   PubMed Web of Science ®Google Scholar
• Rydz N, Swystun LL, Notley C, et al. The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels. Blood. 2013;121(6):5228–5237. doi:10.1182/blood-2012-10-457507
   PubMedGoogle Scholar
• Swystun LL, Ogiwara K, Lai JD, et al. The scavenger receptor SCARA5 is an endocytic receptor for von Willebrand factor expressed by littoral cells in the human spleen. J Thromb Haemost. 2019;17(8):1384–1396. doi:10.1111/jth.14521
   PubMed Web of Science ®Google Scholar
• Swystun LL, Lai JD, Notley C, et al. The endothelial cell receptor stabilin-2 regulates VWF-FVIII complex half-life and immunogenicity. J Clin Investig. 2018;128(9):4057–4073. doi:10.1172/JCI96400
   PubMed Web of Science ®Google Scholar
• Khoo US, Chan KYK, Chan VSF, Lin CLS. DC-SIGN and L-SIGN: the SIGNs for infection. J Mol Med. 2008;86(8):861–874. doi:10.1007/s00109-008-0350-2
   PubMed Web of Science ®Google Scholar
• Lunghi B, Morfini M, Martinelli N, Linari S, Castaman G, Bernardi F. Clinical medicine combination of CLEC4M rs868875 G-carriership and ABO O genotypes may predict faster decay of FVIII infused in hemophilia A patients. J Clin Med. 2022;2022:733. doi:10.3390/jcm11030733
   Google Scholar
• Falkowski M, Schledzewski K, Hansen B, Goerdt S. Expression of stabilin-2, a novel fasciclin-like hyaluronan receptor protein, in murine sinusoidal endothelia, avascular tissues, and at solid/ liquid interfaces. Histochem Cell Biol. 2003;120(5):361–369. doi:10.1007/s00418-003-0585-5
   PubMed Web of Science ®Google Scholar
• Politz O, Gratchev A, Mccourt PAG, et al. Stabilin-1 and-2 constitute a novel family of fasciclin-like hyaluronan receptor homologues. Biochem J. 2002;362:155–164. doi:10.1042/bj3620155
   PubMed Web of Science ®Google Scholar
• Desch KC, Ozel AB, Halvorsen M, et al. Whole-exome sequencing identifies rare variants in STAB2 associated with venous thromboembolic disease. Blood. 2020;136(5):533–541. doi:10.1182/blood.2019004161
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Brown MS. The LDL Receptor. Arterioscler Thromb Vasc Biol. 2009;29(4):431–438. doi:10.1161/ATVBAHA.108.179564
   PubMed Web of Science ®Google Scholar
• Martinelli N, Girelli D, Lunghi B, et al. Polymorphisms at LDLR locus may be associated with coronary artery disease through modulation of coagulation factor VIII activity and independently from lipid profile. Blood. 2010;116(25):5688–5697. doi:10.1182/blood-2010-03-277079
   PubMed Web of Science ®Google Scholar
• Lunghi B, Bernardi F, Martinelli N, et al. Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates. J Thromb Haemost. 2019;17(8):1288–1296. doi:10.1111/jth.14473
   PubMed Web of Science ®Google Scholar
• Grewal PK. The Ashwell-Morell receptor. Methods Enzymol. 2010;479(10):223–241.
   PubMedGoogle Scholar
• Bovenschen N, Rijken DC, Havekes LM, van Vlijmen BJM, Mertens K. The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor. J Thromb Haemost. 2005;3(6):1257–1265. doi:10.1111/j.1538-7836.2005.01389.x
   PubMed Web of Science ®Google Scholar
• Lunghi B, Morfini M, Martinelli N, et al. The asialoglycoprotein receptor minor subunit gene contributes to pharmacokinetics of factor VIII concentrates in hemophilia A. Thromb Haemost. 2022;122(05):715–725. doi:10.1055/a-1591-7869
   PubMed Web of Science ®Google Scholar
• Li H, Fang H, Chang L, et al. TC2N: a novel vital oncogene or tumor suppressor gene in cancers. Front Immunol. 2021;12(1):1–9.
   Google Scholar
• Ye S, Karim ZA, Al HR, Pessin JE, Filipovich AH, Whiteheart SW. Syntaxin-11, but not syntaxin-2 or syntaxin-4, is required for platelet secretion. Blood. 2012;120(12):2484–2492. doi:10.1182/blood-2012-05-430603
   PubMed Web of Science ®Google Scholar
• Ye S, Huang Y, Joshi S, et al. Platelet secretion and hemostasis require syntaxin-binding protein STXBP5. J Clin Investig. 2014;124(10):4517–4528. doi:10.1172/JCI75572
   PubMed Web of Science ®Google Scholar
• Zhu Q, Yamakuchi M, Ture S, et al. Syntaxin-binding protein STXBP5 inhibits endothelial exocytosis and promotes platelet secretion. J Clin Investig. 2014;124(10):4503–4516. doi:10.1172/JCI71245
   PubMed Web of Science ®Google Scholar
• Pelland-Marcotte MC, Carcao MD. Hemophilia in a Changing Treatment Landscape. Hematol Oncol Clin North Am. 2019;33(3):409–423. doi:10.1016/j.hoc.2019.01.007
   PubMed Web of Science ®Google Scholar
• Peters RT, Toby G, Lu Q, et al. Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein. J Thromb Haemost. 2013;11(1):132–141. doi:10.1111/jth.12076
   PubMed Web of Science ®Google Scholar
• Mei B, Pan C, Jiang H, et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood. 2010;116(2):270–279. doi:10.1182/blood-2009-11-254755
   PubMed Web of Science ®Google Scholar
• Carcao MD, Chelle P, Clarke E, et al. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: is there a difference? J Thromb Haemost. 2019;17(7):1085–1096. doi:10.1111/jth.14469
   PubMed Web of Science ®Google Scholar
• Lalezari S, Martin Owitz U, Win Dyga J, et al. Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia. 2014;20(1):e15–e22. doi:10.1111/hae.12294
   PubMed Web of Science ®Google Scholar
• Teitel J, Sholzberg M, Iorio A. Extended half-life factor VIII concentrates in adults with hemophilia A: comparative pharmacokinetics of two products. Res Pract Thromb Haemost. 2021;5(2):349–355. doi:10.1002/rth2.12476
   PubMed Web of Science ®Google Scholar
• Tagliaferri A, Matichecchia A, Rivolta GF, et al. Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience. Blood Transfus. 2020;18(5):374–385. doi:10.2450/2019.0220-19
   PubMed Web of Science ®Google Scholar
• Nummi V, Lehtinen AE, Iorio A, Szanto T, Lassila R. Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: comparison of factor product use, bleed rates and pharmacokinetics. Haemophilia. 2022;28(6):e237–e244. doi:10.1111/hae.14649
   PubMed Web of Science ®Google Scholar
• Shah A, Coyle T, Lalezari S, et al. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: comprehensive pharmacokinetic assessment from clinical studies. Haemophilia. 2018;24(5):733–740. doi:10.1111/hae.13561
   PubMed Web of Science ®Google Scholar
• Shapiro AD, Ragni MV, Kulkarni R, et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J Thromb Haemost. 2014;12(11):1788–1800. doi:10.1111/jth.12723
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A Key Points. Blood. 2014;123(3):317–325. doi:10.1182/blood-2013-10-529974
   PubMed Web of Science ®Google Scholar
• Konkle BA, Stasyshyn O, Chowdary P, et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood. 2015;126(9):1078–1085. doi:10.1182/blood-2015-03-630897
   PubMed Web of Science ®Google Scholar
• Konkle BA, Shapiro AD, Quon DV, et al. BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A. N Engl J Med. 2020;383(11):1018–1027. doi:10.1056/NEJMoa2002699
   PubMed Web of Science ®Google Scholar
• Chhabra ES, Liu T, Kulman J, et al. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice. Blood. 2020;135(17):1484–1496. doi:10.1182/blood.2019001292
   PubMed Web of Science ®Google Scholar